Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(0.07) per share. This is a 250 percent decrease over losses of $(0.02) per share from the same period last year.
Biotech Investors: August’s Key PDUFA Catalysts You Must Know
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the month were new molecular entities, underlining a lack of innovation going on in the sector.
